This September, the Ministry of Health and Welfare has listed human cell immunotherapy as a routine treatment, which is eagerly awaited by many cancer patients. Some of the domestic biomedical companies have also locked up this highly potential cancer treatment market, and are actively seizing the favorable position, ready to invest capital and manpower and introduce foreign technology, so that the anti-cancer field presents a fierce battle situation. In addition, the company is also committed to developing a new generation of cell culture plants, and is developing CAR-T therapy technology for its customers, while Bohui and Xinpin are investing in cancer immunocell therapy to fight for the anti-cancer market after the opening up of the Special Administrative Region of the People's Republic of China.
The Ministry of Health and Welfare announced on September 4, 2008 that it would open up six cell therapy technologies for autologous cell therapy, which is a major adjustment in the field of autologous cell therapy for cancer that is of greatest concern to the biotech industry. The original "Compassionate Therapy" stipulates that the patient must be in "life-threatening or severe disability" and "there is no appropriate drug or alternative therapy in China", and the physician has to set up an "accessory plan" in the human trial and pass the application before it can be carried out; whereas, the current approach incorporates hematological malignant tumors, such as leukemia, multiple myeloma, etc., and a variety of end-stage parenchymal cancers, such as lung cancer, gastric cancer, and stage 1~3 solid cancers through standard therapies. ~The approach includes hematologic malignancies such as leukemia and myeloma, as well as end-stage parenchymal cancers such as lung, gastric, and stage 1 to 3 solid cancers that have failed standard therapy.
Current Immunotherapy Industry Global Market Capitalization
An industry analysis by EvaluatePharma (a private commercial database of more than 4,500 companies and 50,000 products) indicated that the existing global antitumor market is approximately $100 billion, and with the rise of immunotherapy, it is estimated to reach $10 billion by 2020, with the first estimate being that it will reach $1 billion by 2020, with the first estimate being that it will reach $1 billion by 2020, with the first estimate being that it will reach $1 billion by 2020. The initial estimate is that it will reach $150 billion by 2020.
According to the latest information released by the Ministry of Health and Welfare on December 28, 106 - 2015 Cancer Registry Report, the number of new cancers was 105,156, of which about 20,000 were end-stage cancer patients, and the cost of a single treatment per person per year was 50~1 million yuan, conservatively estimating that the cancer cell therapy market in Taiwan is about 10~20 billion NTD.
Domestic biomedical industry actively enter the field of cancer cell therapy?
Biotech companies play an upstream role in manufacturing?
The so-called cancer cell therapy method is to extract blood or tissues from the human body, analyze the cells to be used, such as T cells, NK cells or stem cells, etc., and by professionals in the GTP (Good Practice in Human Cells and Tissues) laboratories, after a rigorous biotechnology experimental process, to replicate a sufficient amount of cells for patients, and then injected back into the human body, in order to achieve the effect of treatment of cancer. The company's products have been used in a number of different ways, including the following
Domestic biotech companies such as Kia, CyberLink, and Advanced Pharmaceuticals have built GTP labs and are negotiating with major medical centers to play the role of upstream manufacturing and cell culture factories, while hospitals are responsible for treatment.
Manufacturers utilize Taiwan's Center for Biotechnology (DCB) to develop the CAR-T therapeutic technology platform Technology alliance
AURORA and Yushiba joined the CAR-T therapeutic technology platform developed by the DCB (Taiwan's Center for Biotechnology) in 2006 and have entered into a strategic alliance that combines AURORA's newest generation of viral-free vector technology and Yushiba's innovative concept of combining antibodies with cellular therapies. This strategic alliance, combined with AURORA's latest generation of non-viral vector technology and Yushibo's innovative concept of using antibodies in combination with cellular therapy, is expected to dramatically shorten the treatment process and reduce treatment costs, as well as improve the existing cellular immunotherapy.
Some biomedical companies have introduced Japanese immunotherapy
GICC held a seminar on August 4 last year and invited Kenichiro Renmi, a Japanese immunology authority, to talk about HITV therapy, which involves injecting dendritic cells directly into solid tumors and using them in combination with conventional treatments such as radiotherapy and chemotherapy, and said that patients who have been paired with patients who are adapted to the therapy have a 70% to 80% chance of being cured. He said that patients who are matched with this therapy have a cure rate of 70% to 80%, and some patients even have a chance for their tumors to disappear completely. Currently, the research team has gone to Japan to receive technology transfer; and recently, the medical team will also go to Japan to learn the whole set of treatment process.
And today (12) Xinpin Biomedical introduced the Japanese marketed "dendritic cell vaccine" and "super NK cell preparation" as the auxiliary vaccine and preparation for immune checkpoint inhibitors, using autoimmune cells to attack the cancer cells, so that the "cold" tumors to turn hot in the hope of enhancing the effectiveness of the existing treatment of immune checkpoint inhibitors.
It is reported that the special management approach to amend the provisions of Article 18, the implementation of cell therapy technology in medical institutions, each year must do the results of the report, including cases, effects, adverse events, etc., the Ministry of Health and Welfare will also be able to publicize the results of the domestic manufacturers of the actual medical performance of the strengths and weaknesses of the time will be at a glance.